News & Articles

Detecting lung cancer early with advanced flow cytometry


CyPath® Lung is a non-invasive, cost-effective, and accurate test to detect early-stage lung cancer in patients at high risk.


Through our subsidiary, OncoSelect® Therapeutics, we are advancing our discoveries to create broad-spectrum cancer therapeutics.

Our Most Recent News, Events, Press Releases

Latest Information

Latest Updates

bioAffinity Technologies Reports Fourth Quarter and Full Year 2022 Financial Results

Conference Call Scheduled for April 3, 2023, at 9:00 a.m. Eastern Time SAN ANTONIO, Texas (March 31, 2023) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company addressing the need for noninvasive detection of early-stage lung cancer and other diseases of the lung, today reported financial results for the three and 12 months ended December 31, 2022. Financial Highlights Raised net proceeds of approximately $6.0 million from an initial public offering (IPO) in September 2022 Converted nearly $16 million in debt, related accrued interest and fair value adjustments into shares of common stock in connection with the IPO Raised an additional $7.8 million from the exercise of warrants and stock options Corporate and Operational Highlights Announced publication in...
Read More
Full Catalog of Prior Articles, News, Events, and Press Releases

Prior Articles

News & Articles

Precision Pathology Services

Learn More about CyPath® Lung

The CyPath® Lung Flow Cytometry Test has been licensed by Precision Pathology Services for commercial sale as a Laboratory Developed Test (LDT).

CyPath® Lung is a non-invasive test that assists clinical decision-making in lung cancer patients whose low-dose computed tomography (LDCT) has demonstrated a suspicious finding.

The test reveals the lung micro-environment by automated analysis of sputum using flow cytometry to characterize cell populations indicative of cancer in the lung.

Physician Portal

Patient Portal

How to Order

CyPath® FAQ